CymitQuimica logo

CAS 1802181-20-9

:

Olmutinib

Description:
Olmutinib is a small molecule inhibitor primarily developed for the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR). It is classified as a tyrosine kinase inhibitor (TKI), targeting the mutant forms of EGFR, particularly those resistant to first-generation TKIs. The compound exhibits high selectivity for the mutated receptor, which enhances its therapeutic efficacy while minimizing off-target effects. Olmutinib is administered orally and has been shown to have a favorable pharmacokinetic profile, allowing for sustained plasma concentrations. Its mechanism of action involves the inhibition of downstream signaling pathways that promote tumor growth and survival. Clinical studies have indicated that Olmutinib can lead to significant tumor regression in patients with EGFR mutations, contributing to improved progression-free survival rates. As with many targeted therapies, potential side effects may include skin rash, diarrhea, and liver enzyme elevation, necessitating careful monitoring during treatment. Overall, Olmutinib represents a promising option in the evolving landscape of targeted cancer therapies.
Formula:C26H26N6O2S
InChI:InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
InChI key:InChIKey=FDMQDKQUTRLUBU-UHFFFAOYSA-N
SMILES:O(C1=C2C(=NC(NC3=CC=C(C=C3)N4CCN(C)CC4)=N1)C=CS2)C5=CC(NC(C=C)=O)=CC=C5
Synonyms:
  • Olmutinib
  • 2-Propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-
  • N-[3-[[2-[[4-(4-Methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide
  • BI 1482694
  • HM 61713
  • HM-61713 (BI-1482694)
  • NSC 163501;ANTIBIOTIC AT-125;U 42126;HM 61713;BI 1482694;HM61713;BI1482694
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 1 products.